Search Results | Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Susan Sheng, Matthew Thayer, Rafael Bejar, Stephen Howell, William Rice

Cancer Res (2020) 80 (16_Supplement): CT239.

DOI: https://doi.org/10.1158/1538-7445.AM2020-CT239

Published: 15 August 2020

View article

Journal Articles

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Nasrin Rastgoo, Matthew Thayer, Khalid Benbatoul, Stephen Howell, William Rice, Hongying Zhang

Cancer Res (2020) 80 (16_Supplement): 4225.

DOI: https://doi.org/10.1158/1538-7445.AM2020-4225

Published: 15 August 2020

View article

Journal Articles

Abstract 2860A: Evolution and characterization of carboplatin resistance at single-cell resolution

Devora Champa, Si Sun, Cheng-Yu Tsai, Stephen Howell, Olivier Harismendy

Cancer Res (2018) 78 (13_Supplement): 2860A.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2860A

Published: 01 July 2018

View article

Journal Articles

Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples

Stephen E. Kurtz, Kevin Watanabe-Smith, Dan Bottomly, Beth Wilmot, Shannon Mcweeney, Andrea Local, Hongying Zhang, Stephen Howell, William Rice, Brian J. Druker, Jeffrey W. Tyner

Cancer Res (2018) 78 (13_Supplement): 791.

DOI: https://doi.org/10.1158/1538-7445.AM2018-791

Published: 01 July 2018

View article

Journal Articles

Abstract 950: Selective cytotoxicity of A6 peptide against ZAP-70 expressing CLL B-cells

Hsien Lai, Suping Zhang, Christina Wu, Liguang Chen, Grace Liu, RongRong Wu, Fitzgerlad Lao, Jian Yu, Laura Rassenti, Michael Choi, Stephen Howell, Malcolm Finlayson, Thomas Kipps

Cancer Res (2014) 74 (19_Supplement): 950.

DOI: https://doi.org/10.1158/1538-7445.AM2014-950

Published: 01 October 2014

View article

Journal Articles

Abstract 1495: Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4.

Xiying Shang, Xinjian Lin, Gerald Manorek, Stephen Howell

Cancer Res (2013) 73 (8_Supplement): 1495.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1495

Published: 15 April 2013

View article

Journal Articles

Abstract 211: Control of integrin expression and signaling by claudin-3 and claudin-4 in ovarian cancer.

Xinjian Lin, Xiying Shang, Gerald Manorek, Stephen Howell

Cancer Res (2013) 73 (8_Supplement): 211.

DOI: https://doi.org/10.1158/1538-7445.AM2013-211

Published: 15 April 2013

View article

Journal Articles

Abstract 1814: Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1

Xinjian Lin, Xiying Shang, Gerald Manorek, Stephen Howell

Cancer Res (2012) 72 (8_Supplement): 1814.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1814

Published: 15 April 2012

View article

Journal Articles

Abstract 4219: Claudin-3 and claudin-4 regulate ovarian cancer growth rate and metastatic potential through effect on integrin and β-catenin signaling

Xiying Shang, Xinjian Lin, Gerald Manorek, Stephen Howell

Cancer Res (2012) 72 (8_Supplement): 4219.

DOI: https://doi.org/10.1158/1538-7445.AM2012-4219

Published: 15 April 2012

View article

Journal Articles

Abstract #2917: Pharmacokinetics and tissue distribution of a novel macromolecular formulation of paclitaxel in nu/nu mice bearing NCI-460 lung cancer xenografts

Xinghe Wang, Gang Zhao, Sang Van, Nan Jiang, Lei Yu, Stephen Howell

Cancer Res (2009) 69 (9_Supplement): 2917.

Published: 01 May 2009

View article

Journal Articles

Abstract #3630: Characterization of recombinant fusion toxin GrB/YCG targeting LHR expressing cancer cells

Isao Kanatani, Xinjian Lin, Gerald Manorek, Xiaoqin Yuan, Lawrence Cheung, Michael Rosenblum, Stephen Howell

Cancer Res (2009) 69 (9_Supplement): 3630.

Published: 01 May 2009

View article

Journal Articles

Abstract #3631: LHR-targeted hCG-gelonin conjugate against mouse Leydig tumor cells

Xinjian Lin, Jingmei Su, Gerald Manorek, Isao Kanatani, John Marks, Michael Rosenblum, Stephen Howell

Cancer Res (2009) 69 (9_Supplement): 3631.

Published: 01 May 2009

View article

Journal Articles

Abstract #3880: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin

Christopher Larson, Brian Blair, Roohangiz Safaei, Stephen Howell

Cancer Res (2009) 69 (9_Supplement): 3880.

Published: 01 May 2009

View article

Journal Articles

Abstract #2951: Differential interaction of cisplatin with the metal binding domains of Cu chaperones and transporters.

Roohangiz Safaei, Brian Blair, Mohammad Maktabi, Preston Adams, Christopher Larson, Stephen Howell

Cancer Res (2009) 69 (9_Supplement): 2951.

Published: 01 May 2009

View article

Journal Articles

Role of mammalian copper transporter (CTR1) in the cellular accumulation of cisplatin, carboplatin and oxaliplatin

Christopher Larson, Nicole Chung, Stephen Howell

Cancer Res (2008) 68 (9_Supplement): 4771.

Published: 01 May 2008

View article

Journal Articles

Antitumor activity of nexil in preclinical animal tumor models

Zhongling Feng, Sanjib Das, Fu Chen, Gang Zhao, Stephen Howell, Lei Yu

Cancer Res (2008) 68 (9_Supplement): 2319.

Published: 01 May 2008

View article

Journal Articles

Pharmacokinetics and tissue distribution of nexil, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing nci-460 lung cancer xenografts

Xinghe wang, Gang Zhao, Sang Van, Nan Jiang, Stephen Howell, Lei Yu

Cancer Res (2008) 68 (9_Supplement): 5738.

Published: 01 May 2008

View article

Journal Articles

Bortezomib inhibits cisplatin-induced down-regulation of its influx transporter and increases cisplatin accumulation in human ovarian carcinoma cells

Danielle Jandial, Christopher Larson, Gregory Elliot, Wolfgang Wrasidlo, Stephen Howell

Cancer Res (2008) 68 (9_Supplement): 3260.

Published: 01 May 2008

View article

Journal Articles

A6 peptide exhibits potent anti chemotactic activity against human breast and ovarian cancer cell lines

Bassam Damaj, Ying Wen, Lisa Schneider, Stephen Howell, Malcolm Finlayson

Cancer Res (2008) 68 (9_Supplement): 1170.

Published: 01 May 2008

View article

Journal Articles

The copper chaperone Atox1 is involved in the intracellular sequestration of cisplatin

Roohangiz Safaei, Michael Rasmussen, Karen Francisco, Stephen Howell

Cancer Res (2007) 67 (9_Supplement): 5631.

Published: 01 May 2007

View article

NARROW

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

Abstract 4225: CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas

Abstract 2860A: Evolution and characterization of carboplatin resistance at single-cell resolution

Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples

Abstract 950: Selective cytotoxicity of A6 peptide against ZAP-70 expressing CLL B-cells

Abstract 1495: Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4.

Abstract 211: Control of integrin expression and signaling by claudin-3 and claudin-4 in ovarian cancer.

Abstract 1814: Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1

Abstract 4219: Claudin-3 and claudin-4 regulate ovarian cancer growth rate and metastatic potential through effect on integrin and β-catenin signaling

Abstract #2917: Pharmacokinetics and tissue distribution of a novel macromolecular formulation of paclitaxel in nu/nu mice bearing NCI-460 lung cancer xenografts

Abstract #3630: Characterization of recombinant fusion toxin GrB/YCG targeting LHR expressing cancer cells

Abstract #3631: LHR-targeted hCG-gelonin conjugate against mouse Leydig tumor cells

Abstract #3880: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin

Abstract #2951: Differential interaction of cisplatin with the metal binding domains of Cu chaperones and transporters.

Role of mammalian copper transporter (CTR1) in the cellular accumulation of cisplatin, carboplatin and oxaliplatin

Antitumor activity of nexil in preclinical animal tumor models

Pharmacokinetics and tissue distribution of nexil, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing nci-460 lung cancer xenografts

Bortezomib inhibits cisplatin-induced down-regulation of its influx transporter and increases cisplatin accumulation in human ovarian carcinoma cells

A6 peptide exhibits potent anti chemotactic activity against human breast and ovarian cancer cell lines

The copper chaperone Atox1 is involved in the intracellular sequestration of cisplatin

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only